47
- Societies
- SSMO,
- SSH
- Categories
- Joint Session
Oral presentations Clinical hemato-oncology
-
Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: A Real-World Analysis from a Single Center
- Presentation time:
- 9 min
- Discussion time:
- 3 min
Speaker: Shaforostova (Inselspital)
-
Real world experience with maintenance treatment after allogeneic hematopoetic cell transplantation for myeloid neoplasia
- Presentation time:
- 9 min
- Discussion time:
- 3 min
Speaker: Sakiz (University Hospital Basel)
-
AL-amyloidosis patients continue to benefit from HDCT with ASCT compared to chemoimmunotherapy only in the daratumumab era.
- Presentation time:
- 9 min
- Discussion time:
- 3 min
Speaker: Bee (Inselspital)
-
Cyclophosphamide-ATG Compared to BEAM-ATG as Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
- Presentation time:
- 9 min
- Discussion time:
- 3 min
-
Performance of ELN Risk Stratifications in a Real-World Setting: A 20-year Analysis of Patients with Acute Myeloid Leukaemia
- Presentation time:
- 9 min
- Discussion time:
- 3 min
-
Longterm-outcome of myeloma patients after high-dose chemotherapy with melphalan alone versus melphalan with bendamustine.
- Presentation time:
- 9 min
- Discussion time:
- 3 min
Speaker: Fischer (Inselspital)
-
Swiss Real-World Experience with Tafasitamab and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The SWISS-MIND Study
- Presentation time:
- 9 min
- Discussion time:
- 3 min
Speaker: Gassmann (University of Basel)